Dr. Heimbach is a Senior Principal Scientist (Director) at Merck & Co. in the Biologics Development and Biopharmaceutics Group which is part of the Sterile and Specialty Products Group. There he serves as a biopharmaceutics and PBBM/PBPK expert for oral and long-acting injectables drug development, which includes establishing the bioequivalence safe space of new drug candidates using Physiologically Based Biopharmaceutics Modeling (PBBM). Prior to that Tycho was Director in DMPK at Novartis where he led a global PBPK modeling group and served as PBPK and biopharmaceutics expert and implemented PBPK/PBBM for oncology drugs.

Tycho is currently serving as the Merck representative on the PBBM Innovation & Quality (IQ) Consortium Working Group and was one of the core organizers for the 2023 Global PBBM M-CERSI-FDA workshop. He has authored/coauthored ~70 peer-reviewed publications in ADME, PBPK and formulation sciences and was recognized as an AAPS Fellow in 2021.